Literature DB >> 28956175

Rasagiline for dysexecutive symptoms during wearing-off in Parkinson's disease: a pilot study.

Domiziana Rinaldi1, Francesca Assogna2,3, Michela Sforza1, Stefania Tagliente1, Francesco E Pontieri4,5.   

Abstract

Wearing-off refers to the predictable worsening of motor and sometimes non-motor symptoms of Parkinson's disease occurring at the end of levodopa dose that improves with the next drug dose. Here, we investigated the efficacy of rasagiline on executive functions at the end of levodopa dose in patients displaying symptoms of wearing-off. Rasagiline was well-tolerated and produced a significant improvement at the Frontal Assessment Battery, together with improvement of motor symptoms at the end of levodopa dose. These results suggest that treatment of motor symptoms of wearing-off with rasagiline may be accompanied by improvement of executive functions, and further support the need for optimizing dopamine replacement therapy in fluctuating Parkinson's disease patients.

Entities:  

Keywords:  Cognition; Frontal Assessment Battery; Parkinson’s disease; Rasagiline; Wearing-off

Mesh：

Substances：

Year:  2017        PMID： 28956175     DOI： 10.1007/s10072-017-3123-2

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


  8 in total

1.  Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders.

Authors:  Roberto Marconi; Angelo Antonini; Paolo Barone; Carlo Colosimo; Tania P Avarello; Edo Bottacchi; Antonino Cannas; Maria G Ceravolo; Roberto Ceravolo; Giulio Cicarelli; Rosa M Gaglio; Luisa Giglia; Francesco Iemolo; Michela Manfredi; Giuseppe Meco; Alessandra Nicoletti; Massimo Pederzoli; Alfredo Petrone; Antonio Pisani; Francesco E Pontieri; Rocco Quatrale; Silvia Ramat; Rossana Scala; Giampiero Volpe; Salvatore Zappulla; Anna Rita Bentivoglio; Fabrizio Stocchi; Giorgio Trianni; Paolo Del Dotto; Danilo De Gaspari; Lucia Grasso; Francesca Morgante; Gabriella Santangelo; Giovanni Fabbrini; Letterio Morgante
Journal:  Neurol Sci       Date:  2011-11-03       Impact factor: 3.307

2.  The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.

Authors:  Hasmet A Hanagasi; Hakan Gurvit; Pınar Unsalan; Hilal Horozoglu; Nese Tuncer; Aynur Feyzioglu; Dilek Ince Gunal; Gorsev G Yener; Raif Cakmur; Huseyin A Sahin; Murat Emre
Journal:  Mov Disord       Date:  2011-04-15       Impact factor: 10.338

3.  The effect of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson's disease: support from functional MRI.

Authors:  Penny A MacDonald; Alex A MacDonald; Ken N Seergobin; Ruzbeh Tamjeedi; Hooman Ganjavi; Jean-Sebastien Provost; Oury Monchi
Journal:  Brain       Date:  2011-05       Impact factor: 13.501

Review 4.  Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force.

Authors:  Bruno Dubois; David Burn; Christopher Goetz; Dag Aarsland; Richard G Brown; Gerald A Broe; Dennis Dickson; Charles Duyckaerts; Jefferey Cummings; Serge Gauthier; Amos Korczyn; Andrew Lees; Richard Levy; Irene Litvan; Yoshikuni Mizuno; Ian G McKeith; C Warren Olanow; Werner Poewe; Cristina Sampaio; Eduardo Tolosa; Murat Emre
Journal:  Mov Disord       Date:  2007-12       Impact factor: 10.338

Review 5.  Levodopa-related wearing-off in Parkinson's disease: identification and management.

Authors:  Rajesh Pahwa; Kelly E Lyons
Journal:  Curr Med Res Opin       Date:  2009-04       Impact factor: 2.580

Review 6.  Rasagiline for the treatment of Parkinson's disease: an update.

Authors:  Fabrizio Stocchi; Chiara Fossati; Margherita Torti
Journal:  Expert Opin Pharmacother       Date:  2015       Impact factor: 3.889

7.  The sensitivity and specificity of the 9-item Wearing-off Questionnaire.

Authors:  M A Stacy; J M Murphy; D R Greeley; R M Stewart; H Murck; X Meng
Journal:  Parkinsonism Relat Disord       Date:  2007-09-27       Impact factor: 4.891

8.  The early course of affective and cognitive symptoms in de novo patients with Parkinson's disease.

Authors:  Gianfranco Spalletta; Robert G Robinson; Luca Cravello; Francesco E Pontieri; Mariangela Pierantozzi; Alessandro Stefani; Jeffrey D Long; Carlo Caltagirone; Francesca Assogna
Journal:  J Neurol       Date:  2014-04-03       Impact factor: 4.849
  8 in total
  5 in total

1.  Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson's disease: a systematic review.

Authors:  De-Qi Jiang; Hua-Kun Wang; Yan Wang; Ming-Xing Li; Li-Lin Jiang; Yong Wang
Journal:  Neurol Sci       Date:  2019-08-24       Impact factor: 3.307

2.  News on the journal Neurological Sciences in 2017.

Authors:  Ilaria Di Donato; Antonio Federico
Journal:  Neurol Sci       Date:  2018-01       Impact factor: 3.307

3.  Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson's disease: A systematic review.

Authors:  Takashi Tsuboi; Yuki Satake; Keita Hiraga; Katsunori Yokoi; Makoto Hattori; Masashi Suzuki; Kazuhiro Hara; Adolfo Ramirez-Zamora; Michael S Okun; Masahisa Katsuno
Journal:  NPJ Parkinsons Dis       Date:  2022-06-13

4.  Functional and Cognitive Improvement After an Intensive Inpatient Multidisciplinary Rehabilitation Program in Mild to Severe Parkinson's Disease: A Retrospective and Observational Study.

Authors:  Mario Meloni; Francesca Lea Saibene; Sonia Di Tella; Monica Di Cesare; Francesca Borgnis; Raffaello Nemni; Francesca Baglio
Journal:  Front Neurol       Date:  2021-03-18       Impact factor: 4.003

Review 5.  The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease.

Authors:  Giovanni Abbruzzese; Paolo Barone; Leonardo Lopiano; Fabrizio Stocchi
Journal:  Drug Des Devel Ther       Date:  2021-06-10       Impact factor: 4.162
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.